Alvotech initiates confirmatory patient study for avt05, a proposed biosimilar for simponi® and simponi aria®

Alvotech (nasdaq: alvo), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today the initiation of alvotech's confirmatory patient study for avt05, a biosimilar candidate to simponi® and simponi aria® (golimumab). the objective of the clinical study is to compare the efficacy, safety, and immunogenicity of avt05 and simponi® in adult patients with moderate to severe rheumatoid arthritis.
ALVO Ratings Summary
ALVO Quant Ranking